Axiom Investment Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Axiom Investment Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$95.6K	Buy	604 +400	+196%	+$54.1K	0.06%	161
2026 Q1	$26.1K	Buy	+204	New	+$25.5K	0.02%	251
2022 Q1	–	Sell	-225	Closed	-$25K	–	154
2021 Q4	$25K	Buy	+225	New	+$27.1K	0.02%	130
2021 Q3	–	Sell	-1,500	Closed	-$203K	–	169
2021 Q2	$203K	Sell	1,500 -1,257	-46%	-$165K	0.16%	127
2021 Q1	$374K	Buy	2,757 +2,616	+1,855%	+$392K	0.3%	78
2020 Q4	$388K	Sell	141 -2,612	-95%	-$335K	0.35%	65
2020 Q3	$307K	Buy	2,753 +3	+0.1%	+$336	0.35%	75
2020 Q2	$308K	Buy	+2,750	New	+$271K	0.41%	66

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Axiom Investment Management's XBI Position: Q2 2026 in Review

Axiom Investment Management increased its State Street SPDR S&P Biotech ETF (XBI) stake by 196% in Q2 2026, buying an estimated $54.1K and bringing the position to 604 shares worth $95.6K. The position accounts for 0.06% of the portfolio, ranked #161.

Axiom Investment Management first reported a position in XBI in Q2 2020 and has held it in 8 quarters since. The position peaked at $388K in Q4 2020. 932 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Axiom Investment Management held 604 shares of State Street SPDR S&P Biotech ETF worth $95.6K as of Q2 2026.
Axiom Investment Management bought 400 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $54.1K.
State Street SPDR S&P Biotech ETF made up 0.06% of Axiom Investment Management's portfolio in Q2 2026, its #161 holding.
Axiom Investment Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2020 and has held it in 8 quarters since.
Axiom Investment Management's State Street SPDR S&P Biotech ETF position peaked at $388K in Q4 2020.
932 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Axiom Investment Management's 13F filing for Q2 2026, filed 31 Jul 2026.